A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models

Rapamycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell carcinoma (RCC). Currently approved agents inhibit mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). However, the mTOR kinase exists in two distinct multiprotein complexes, mTORC1 and mTORC2...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hao, Berel, Dror, Wang, Yanping, Li, Ping, Bhowmick, Neil A., Figlin, Robert A., Kim, Hyung L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551765/
https://www.ncbi.nlm.nih.gov/pubmed/23349989
http://dx.doi.org/10.1371/journal.pone.0054918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551765/
https://www.ncbi.nlm.nih.gov/pubmed/23349989
http://dx.doi.org/10.1371/journal.pone.0054918

Ejemplares similares